CLL relapse on ibrutinib is mainly due to the acquisition of mutations in BTK or PLCG2, its direct downstream target (Woyach, 2017; Maddocks et al., 2015; Woyach et al., 2014). Here, BTK is linked to B-cell chronic lymphocytic leukemia.